References
- Wells K B. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. American Journal of Psychiatry 1999; 156: 5–10
- Healy D. The Antidepressant Era. Harvard University Press, Cambridge 1997
- Janicak P G, Davis J M, Preskorn S H, Ayd F J. Principles and practice of psychopharmacotherapy. Management of an acute depressive episode. Williams & Wilkins, Baltimore, MD 1993; 226–246
- Agency for Health Care Policy and Research. Treatment of depression newer pharmacotherapies. Summary. Report from University of Texas Health Science Center, San Antonio, TX 1999, Evidence Report No. 7.
- Schatzberg A. Antidepressant effectiveness in severe depression and melancholia. Journal of Clinical Psychiatry 1999; 60: 14–21, (Suppl. 4)
- The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–146
- Overall J E, Hollister L E, Porkorny A D, Casey J R, Katz G. Drug therapy in depressions. Controlled evaluation of imipramine, isocarboxazid, dextroamphetamine-amobarbital and placebo. Clinical Pharmacology and Therapeutics 1962; 3: 16–22
- Medical Research Council. Clinical trial of the treatment of depressive illness. British Medical Journal 1965; 1: 831–836
- Lader M, Herrington R. Biological Treatments in Psychiatry. 2nd ed. Oxford University Press, Oxford 1996
- Danish University Antidepressant Group. Citalopram. Clinical effect profile and comparison with Clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 1986; 90: 131–138
- Danish University Antidepressant Group. Paroxetine. A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than Clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18: 289–299
- Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1993; 28: 105–116
- Roose S P, Glassman A H, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry 1994; 151: 1735–1739
- Peselow E D, Sanfilip M P, Difiglia Q, Fieve R R. Melancholic/endogenous depression and response to somatic treatment and placebo. American Journal of Psychiatry 1992; 149: 1324–1334
- Nelson J C, Mazure C M, Jadow P I. Characteristics of desipramine-refractory depression. Journal of Clinical Psychiatry 1994; 55: 12–19
- Fava M, Uebelacker L A, Alpert J E, Nierenberg A, Pava J A, Rosenbaum J F. Major depressive sub-types and treatment response. Biological Psychiatry 1997; 42: 568–576
- Parker G, Hadzi-Pavlovic D. Melancholia. A disorder of movement and mood. Cambridge University Press, New York 1996
- American Psychiatric Association. Treatment of Psychiatric Disorders, 3. American Psychiatric Association, Washington 1989
- Crismon M L, Trivedie M, Pigott T A, et al. The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. Journal of Clinical Psychiatry 1999; 60: 142–156
- Hylan T R, Kotsanos J G, Anderson J S, et al. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: an application to evaluating alternative antidepressants. American Journal of Managed Care 1996; 2: 1211–1223
- Rosenbaum J F, Hylan T R. Costs of depressive Disorders. Evidence and practice in psychiatry: depressive disorders, M Maj. World Psychiatric Association, Geneva, (in press)
- Parker G, Roy K, Hadzi-Pavlovic D, et al. Sub-typing depression by clinical features: the Australasian data base. Acta Psychiatrica Scandinavica, (in press)
- Abrams R. Electroconvulsive therapy. 3rd ed. Oxford University Press, New York 1997
- Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. American Psychiatric Association, Washington, DC 1999
- Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Australian and New Zealand Journal of Psychiatry 1999; 33: 323–327
- Beerworth E E, Tiller J WG. Liability in prescribing choice: the example of the antidepressants. Australian and New Zealand Journal of Psychiatry 1998; 32: 560–566